What is Kaleido?
Kaleido operates at the intersection of medical engineering and patient empowerment, focusing on the design and manufacturing of personalized insulin pump systems. By prioritizing user-friendly interfaces and advanced hardware, the company addresses the complex needs of individuals living with diabetes, allowing for greater autonomy and confidence in daily health management. Its market position is defined by a commitment to high-precision engineering and a deep understanding of the clinical requirements inherent in chronic disease management. As a key player in the Dutch health-tech ecosystem, Kaleido continues to refine its technological stack to meet the rigorous demands of international regulatory standards and patient expectations.
How much funding has Kaleido raised?
Kaleido has raised a total of $108.9M across 2 funding rounds:
Series B
$10.9M
Series D
$98M
Series B (2016): $10.9M, investors not publicly disclosed
Series D (2026): $98M led by Innovation Industries, Venturing, and ROM Utrecht Region
Key Investors in Kaleido
Innovation Industries
Innovation Industries is a European venture capital fund that specializes in investing in impactful deep tech companies focused on sustainability and scalability.
Venturing
We Are Venturing offers comprehensive support to both starting and growing companies, particularly in the technological and marketing sectors.
ROM Utrecht Region
ROM Utrecht Region provides support for innovative entrepreneurs in the Utrecht region, offering assistance with financing, innovation, and international market entry.
What's next for Kaleido?
With the successful closure of this latest funding round, Kaleido is expected to prioritize the commercial scaling of its insulin delivery platforms. The strategic roadmap likely includes the optimization of supply chain logistics and the expansion of its international footprint, particularly in markets where demand for personalized diabetes care is surging. Furthermore, the company is well-positioned to invest in research and development to iterate on its existing hardware, potentially integrating digital health features that enhance data connectivity and patient monitoring. As the firm matures, the focus will shift toward long-term sustainability and the establishment of strategic partnerships with healthcare providers to integrate its systems into standard clinical workflows, thereby solidifying its role as a leader in the medical device sector.
See full Kaleido company page
